ARTICLE | Product Development
Actemra anti-IL-6 data in COVID-19 outshines Regeneron’s Kevzara readout
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 28, 2020 1:07 AM UTC
Regeneron shed $2.1 billion in market cap Monday after an IDMC recommended amendments that would narrow the scope of its Phase III trial of Kevzara sarilumab in advanced COVID-19 patients. Also likely weighing on the company’s stock, an investigator-led Phase II trial yielded positive top-line data for Actemra tocilizumab, another IL-6 inhibitor being tested for COVID-19.
But Regeneron did unveil positive late-stage lung cancer data for PD-1 inhibitor Libtayo cemiplimab-rwlc...